Please check your internet connection and try again.
# Piperacillin-Tazobactam
## Overview
Piperacillin-tazobactam is a combination antibiotic consisting of piperacillin, a broad-spectrum penicillinase-susceptible penicillin antibiotic, and tazobactam, a beta-lactamase inhibitor. It is active against many Gram-positive, Gram-negative, and anaerobic bacteria.
## Primary Indications
* Complicated intra-abdominal infections
* Complicated skin and skin-structure infections
* Community-acquired pneumonia
* Nosocomial pneumonia
* Febrile neutropenia (often part of empiric therapy)
* Bacterial infections due to piperacillin-susceptible organisms that are resistant to other penicillins or cephalosporins, including those caused by *Pseudomonas aeruginosa*.
## Adult Dosing
* **Standard Dose:** 3.375 g every 6 hours or 4.5 g every 8 hours. This corresponds to piperacillin 3 g / tazobactam 0.375 g or piperacillin 4 g / tazobactam 0.5 g, respectively.
* **Severe Infections/Nosocomial Pneumonia:** 4.5 g every 6 or 8 hours, administered over at least 30 minutes. Dosing frequency and duration depend on the severity of illness and clinical response. Some protocols may recommend extended or continuous infusions for *Pseudomonas aeruginosa* infections.
## Pediatric Dosing
Dosing in pediatric patients (≥ 3 months of age) is typically based on the piperacillin component:
* **Complicated Intra-abdominal Infections:** 100 mg piperacillin/kg/dose every 8 hours.
* **Complicated Skin and Skin-Structure Infections:** 75 mg piperacillin/kg/dose every 6 hours.
* **Febrile Neutropenia:** 100 mg piperacillin/kg/dose every 8 hours.
* **Maximum Dose:** Do not exceed the adult maximum dose of 4 g piperacillin per dose. Tazobactam is dosed in proportion to piperacillin. Renal adjustments are critical.
## Dose Adjustments
**Renal Impairment:**
* **CrCl > 40 mL/min:** No adjustment needed.
* **CrCl 20-40 mL/min:** 2.25 g (piperacillin 2 g / tazobactam 0.25 g) or 3.375 g (piperacillin 3 g / tazobactam 0.375 g) every 8 hours; 4.5 g (piperacillin 4 g / tazobactam 0.5 g) every 8 hours.
* **CrCl < 20 mL/min:** 2.25 g every 8 hours or 3.375 g every 12 hours.
* **Hemodialysis:** 2.25 g or 3.375 g every 12 hours, plus an additional dose of 0.75 g after each dialysis session.
Dosing adjustments for pediatric patients with renal impairment require careful calculation based on actual body weight and renal function.
## Contraindications
* Known serious hypersensitivity to piperacillin, tazobactam, other penicillinase-resistant penicillins, or any component of the formulation.
## Adverse Effects
* **Common:** Diarrhea, nausea, vomiting, rash, headache, insomnia, constipation, liver function test abnormalities.
* **Serious:** Hypersensitivity reactions (anaphylaxis), *Clostridioides difficile*-associated diarrhea (CDAD), seizures (especially at high doses or with renal impairment), hematologic effects (neutropenia, thrombocytopenia, eosinophilia, anemia), interstitial nephritis.
## Key Drug Interactions
* **Probenecid:** Increases piperacillin-tazobactam serum concentrations; concurrent administration is generally avoided.
* **Neuromuscular blocking agents (e.g., vecuronium):** Piperacillin may prolong the neuromuscular blockade.
* **Warfarin:** Piperacillin may decrease INR. Monitor INR closely and adjust warfarin dose as needed.
* **Methotrexate:** Piperacillin may decrease methotrexate clearance. Monitor methotrexate levels.
* **Bacteriostatic antibiotics:** May antagonize the bactericidal effect of piperacillin-tazobactam.
## Monitoring
* Renal function (CrCl) for dose adjustments.
* Liver function tests (LFTs).
* Complete blood count (CBC) for hematologic changes, especially with prolonged therapy.
* Signs and symptoms of hypersensitivity reactions.
* Signs and symptoms of *Clostridioides difficile* infection.
* Clinical signs of infection and culture results for therapeutic efficacy.
## Clinical Pearls
* Piperacillin-tazobactam is often administered via intermittent infusion over 30 minutes, but extended or continuous infusions may improve outcomes in certain serious infections, particularly those caused by *Pseudomonas aeruginosa*, and may reduce the risk of nephrotoxicity. Specific protocols for infusion strategies should be consulted.
* The risk of seizures is increased in patients with renal impairment and those receiving high doses.
* Due to its broad spectrum, piperacillin-tazobactam can disrupt normal gut flora and lead to *C. difficile* infection.
* For pediatric dosing, precise calculation based on weight and renal function is crucial. Specific institutional protocols should be followed.
***
*This information is intended for clinical professionals. Always verify current prescribing information from the manufacturer's package insert or a reliable drug information database before making clinical decisions.*
